Intel Genx Technologies Corp. IGXT
We take great care to ensure that the data presented and summarized in this overview for IntelGenx Technologies Corp. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in IGXT
Top Purchases
Top Sells
About IGXT
IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.
Insider Transactions at IGXT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 30
2022
|
Horst G Zerbe Director |
BUY
Open market or private purchase
|
Direct |
19,000
+2.53%
|
$0
$0.13 P/Share
|
|
Sep 29
2022
|
Andre Godin President and CFO |
BUY
Open market or private purchase
|
Direct |
5,000
+1.6%
|
$0
$0.12 P/Share
|
|
Sep 28
2022
|
Andre Godin President and CFO |
BUY
Open market or private purchase
|
Direct |
9,000
+2.88%
|
$0
$0.14 P/Share
|
|
Sep 27
2022
|
Andre Godin President and CFO |
BUY
Open market or private purchase
|
Direct |
1,000
+0.34%
|
$0
$0.13 P/Share
|
|
Sep 26
2022
|
Tommy Kenny SVP IP Legal Affairs Subsid |
BUY
Open market or private purchase
|
Direct |
19,000
+12.06%
|
$0
$0.14 P/Share
|
|
Sep 23
2022
|
Tommy Kenny SVP IP Legal Affairs Subsid |
BUY
Open market or private purchase
|
Direct |
8,000
+6.27%
|
$0
$0.15 P/Share
|
|
Sep 22
2022
|
Tommy Kenny SVP IP Legal Affairs Subsid |
BUY
Open market or private purchase
|
Direct |
2,000
+1.76%
|
$0
$0.15 P/Share
|
|
Sep 22
2022
|
Tommy Kenny SVP IP Legal Affairs Subsid |
BUY
Open market or private purchase
|
Direct |
23,500
+17.67%
|
$0
$0.14 P/Share
|
|
Sep 21
2022
|
Dana Matzen VP Business & Corp. Dev |
BUY
Open market or private purchase
|
Direct |
25,000
+25.0%
|
$0
$0.14 P/Share
|
|
Sep 21
2022
|
Andre Godin President and CFO |
BUY
Open market or private purchase
|
Direct |
20,000
+6.38%
|
$0
$0.13 P/Share
|
|
Jul 07
2022
|
Ingrid Zerbe Corporate Secretary |
BUY
Other acquisition or disposition
|
Direct |
366,144
+18.01%
|
$0
$0.26 P/Share
|
|
Jul 07
2022
|
Andre Godin President and CFO |
BUY
Other acquisition or disposition
|
Direct |
73,228
+10.77%
|
$0
$0.26 P/Share
|
|
Mar 30
2022
|
Dana Matzen VP Business & Corp. Dev |
BUY
Open market or private purchase
|
Direct |
25,000
+33.33%
|
$0
$0.26 P/Share
|
|
Jun 08
2021
|
Dana Matzen VP Business & Corp. Dev |
BUY
Open market or private purchase
|
Indirect |
10,000
+50.0%
|
$0
$0.48 P/Share
|
|
Apr 13
2021
|
Dana Matzen VP Business & Corp. Dev |
BUY
Open market or private purchase
|
Direct |
25,000
+50.0%
|
$0
$0.49 P/Share
|
|
Apr 07
2021
|
Tommy Kenny SVP IP Legal Affairs Subsid |
BUY
Open market or private purchase
|
Direct |
20,000
+7.49%
|
$0
$0.45 P/Share
|
|
Apr 07
2021
|
Andre Godin President and CFO |
BUY
Open market or private purchase
|
Direct |
20,000
+9.08%
|
$0
$0.44 P/Share
|
|
Apr 01
2021
|
Bernard Boudreau Director |
BUY
Open market or private purchase
|
Direct |
12,500
+7.79%
|
$0
$0.47 P/Share
|
|
Mar 30
2021
|
Bernard Boudreau Director |
BUY
Open market or private purchase
|
Direct |
12,500
+8.45%
|
$0
$0.4 P/Share
|
|
Jan 06
2021
|
Ingrid Zerbe Corporate Secretary |
SELL
Open market or private sale
|
Direct |
500
-0.16%
|
$0
$0.24 P/Share
|